Top Markets
Coin of the day
Angion Biomedica Corp. Angion Biomedica Corp.

Angion Biomedica Corp.

ANGN
株式のランク #27858
Angion Biomedica Corp. operates as a biopharmaceutical enterprise,... Angion Biomedica Corp. operates as a biopharmaceutical enterprise, concentrating its efforts on the identification, advancement, and market introduction of small molecule treatments for severe organ damage and scarring conditions. Its primary investigational compound, ANG-3070, is an orally administered tyrosine kinase receptor inhibitor currently being developed to address fibrotic ailments, particularly those impacting the kidneys and lungs. The company's product pipeline also features ANG-3777, a hepatocyte growth factor mimetic engineered to treat acute organ injuries like delayed graft function, in addition to initiatives for ROCK2 inhibitors targeting fibrotic diseases and a CYP11B2 inhibitor program. Established in 1998, Angion Biomedica Corp. maintains its headquarters in Uniondale, New York.
株価
$1.00
最終同期: 2023-06-01
時価総額
$30.11M
変化(1日)
2.04%
変化(1年)
0.00%
US
取引 Angion Biomedica Corp. (ANGN)

カテゴリー

Angion Biomedica Corp.(ANGN)の配当履歴
Angion Biomedica Corp.(証券コード:ANGN)は合計で0回の配当を行いました。
すべての配当の合計(株式分割調整済み)は:0.00
配当利回り(TTM):0
2026から2026までのAngion Biomedica Corp.(ANGN)の配当履歴
年間配当支払い
配当(株式分割調整済み) 変化
提供された日付のデータは十分ではありません。
すべての配当支払いの一覧
配当 変化
提供された日付のデータは十分ではありません。
同業他社や競合企業の配当履歴
企業 配当支払い回数
0.00%
US
0.00%
US
0.00%
NL
64.00%
AU
0.00%
CH